Lung Carcinoma is the 2nd most common cancer worldwide, with more than 2.2 million cases recorded globally in the year 2020, as well as 1.8 million deaths. It is the most common cancer in men and the 2nd most common cancer in women, with an estimated lifetime risk of developing the disease of 1 in 15 for men and 1 in 17 for women. Whilst being the most prevalent cancer, it is important to note that smoking is the single biggest risk factor for developing Lung Cancer, with over 70% of cases being estimated to have been caused by tobacco smoke, and excessive smoking potentially leading to as much as a 25x increase in the likelihood of the disease developing.
Mortality rates have been steadily dropping globally due to declining smoking rates, especially in younger generations who are now more aware of the potential dangers, but also because of the increasing advancements being made in our understanding of the disease. Improved screening methods mean many more cases are now caught earlier than they would otherwise have been, and our ever-advancing ranges of treatments can begin earlier than they could have previously. Recent advances in sequencing technology, computational approaches, and our biological understanding of lung cancer have revolutionized how we diagnose, prognosticate, and treat lung carcinoma. Genetic studies into this disease have revealed a plethora of information which can be used to combat the Cancer, such as novel biomarkers and gene signatures, as well as opening the door to more of a ‘personalized medicine’ approach.
This Research Topic will aim to attract high quality manuscripts based around the topic of the genomics and molecular genetics of Lung Cancer. We welcome development of novel computational methods, re-analysis of existing data that reveals novel biological insight that has the potential to transform patient care, development of methods for multi-omics integration of sparse datasets that leads to novel outcomes, and research that leads to overcoming challenges outlined leading to broader implementation of precision medicine. The collection will aim to serve as a hub of knowledge for researchers, where insights and key advances in genomics coupled with other clinical information such as histopathology, radiographic imagining, and patient chart information can be presented and shared, and progress can be made towards the eventual goal of a complete understanding of this complex disease.
Bioinformatic studies are welcome, however, these should not be based solely on analysis of publicly available datasets such as TCGA. It is essential to have an independent validation cohort for statistically significant confirmation of the findings communicated. Exceptions can be made for analyses combining multiple datasets and novel in silico methodologies
Lung Carcinoma is the 2nd most common cancer worldwide, with more than 2.2 million cases recorded globally in the year 2020, as well as 1.8 million deaths. It is the most common cancer in men and the 2nd most common cancer in women, with an estimated lifetime risk of developing the disease of 1 in 15 for men and 1 in 17 for women. Whilst being the most prevalent cancer, it is important to note that smoking is the single biggest risk factor for developing Lung Cancer, with over 70% of cases being estimated to have been caused by tobacco smoke, and excessive smoking potentially leading to as much as a 25x increase in the likelihood of the disease developing.
Mortality rates have been steadily dropping globally due to declining smoking rates, especially in younger generations who are now more aware of the potential dangers, but also because of the increasing advancements being made in our understanding of the disease. Improved screening methods mean many more cases are now caught earlier than they would otherwise have been, and our ever-advancing ranges of treatments can begin earlier than they could have previously. Recent advances in sequencing technology, computational approaches, and our biological understanding of lung cancer have revolutionized how we diagnose, prognosticate, and treat lung carcinoma. Genetic studies into this disease have revealed a plethora of information which can be used to combat the Cancer, such as novel biomarkers and gene signatures, as well as opening the door to more of a ‘personalized medicine’ approach.
This Research Topic will aim to attract high quality manuscripts based around the topic of the genomics and molecular genetics of Lung Cancer. We welcome development of novel computational methods, re-analysis of existing data that reveals novel biological insight that has the potential to transform patient care, development of methods for multi-omics integration of sparse datasets that leads to novel outcomes, and research that leads to overcoming challenges outlined leading to broader implementation of precision medicine. The collection will aim to serve as a hub of knowledge for researchers, where insights and key advances in genomics coupled with other clinical information such as histopathology, radiographic imagining, and patient chart information can be presented and shared, and progress can be made towards the eventual goal of a complete understanding of this complex disease.
Bioinformatic studies are welcome, however, these should not be based solely on analysis of publicly available datasets such as TCGA. It is essential to have an independent validation cohort for statistically significant confirmation of the findings communicated. Exceptions can be made for analyses combining multiple datasets and novel in silico methodologies